$235 Million

ADC Therapeutics

Follow-on Offering

Bookrunner, September 2020

ADC Therapeutics

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company developing and commercializing highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The Company is leveraging its R&D strengths, target selection and preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. The Company’s hematology franchise comprises three clinical-stage product candidates, loncastuximab tesirine (Lonca), camidanlumab tesirine (Cami) and ADCT-602. The Company’s solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701.